Idiopathic pulmonary fibrosis

The PBS subsidises nintedanib for patients with idiopathic pulmonary fibrosis.

Treatment with nintedanib can be subsidised through the Pharmaceutical Benefits Scheme (PBS) under section 85 of the National Health Act 1953 for patients with idiopathic pulmonary fibrosis.

Patient eligibility

Patients must meet the relevant criteria in the restrictions and be eligible for the PBS.

The Schedule of Pharmaceutical Benefits on the PBS website outlines restrictions for prescribing nintedanib.

Initial treatment

Make all initial applications for authority approval to prescribe nintedanib for the treatment of idiopathic pulmonary fibrosis in writing and:

All applications must include a completed:

Initial grandfather treatment

For patients who received non PBS subsidised nintedanib treatment for idiopathic pulmonary fibrosis before 1 May 2017, make all initial grandfather applications in writing and:

All applications must include a completed:

Continuing treatment

Applications for continuing treatment can be made by calling the PBS Complex Drugs Programs enquiry line.

Further information

For more information contact the PBS Complex Drugs Programs enquiry line.

Page last updated: 1 May 2017

This information was printed Thursday 25 May 2017 from humanservices.gov.au/health-professionals/enablers/idiopathic-pulmonary-fibrosis It may not include all of the relevant information on this topic. Please consider any relevant site notices at humanservices.gov.au/siteinformation when using this material.